BioSpace News Archive

RELIEF THERAPEUTICS Holding AG announced that it has signed and closed the definitive agreement to acquire all outstanding shares of APR Applied Pharma Research S.A., a privately held Swiss pharmaceutical company with over 25 years’ experience in identifying, developing and commercializing known molecules engineered with drug delivery systems in niche and rare diseases on a global basis.

POC devices or point of care devices are mainly used for medical diagnostic tests. These tests are conducted at a time and place convenient for patient care.

Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that the Phase 3 ORCA-2 trial of cytisinicline has reached its enrollment target of 750 adult smokers.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced positive results from its Phase 1b clinical trial of CVL-231, a novel muscarinic M4-selective Positive Allosteric Modulator, in adult patients with schizophrenia.

Synthetic Biologics, Inc., a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal diseases in areas of high unmet need, announced that patient dosing and observation has been completed in its Phase 1, open label, single-ascending dose clinical trial of SYN-020 intestinal alkaline phosphatase.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, announced that Andrew Robbins, Chief Executive Officer and President, will present at the Ladenburg Thalmann Virtual Healthcare Conference on Wednesday, July 14th, from 2:00-2:25pm ET.

Anova Enterprises, Inc., an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, and the industry’s first collaborative ‘learning system’, announced a partnership with the NeOnc Technologies, Inc. to accelerate the development of NEO100 for patients with IDH1 mutated gliomas.

Boston Children’s Hospital and ElevateBio announced that they have entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Children’s Hospital with an introduction to Boston Children’s translational research capabilities.

Carmot Therapeutics, Inc., a clinical-stage biotechnology company applying its proprietary therapeutic platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer, announced that in connection with the recent U.S. FDA approval and commercial launch of Amgen’s LUMAKRAS, Carmot is eligible to receive royalty payments from future sales.